SAFETY AND CLINICAL ACTIVITY OF RP6530, A DUAL PI3Kδ/γ INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES: FINAL ANALYSIS OF A PHASE 1 MULTI‐CENTER STUDY
Sign Up to like & getrecommendations! Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_133
Abstract: patients were analyzed by flow cytometry and modeled against CAR T cell levels. In vivo CAR T‐cell levels were measured by qPCR. T‐cell expansion during production (fold expansion/total days in culture) was compared with CAR… read more here.
Keywords: car cell; expansion; analysis; axi cel ... See more keywords
Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Hematology/oncology and stem cell therapy"
DOI: 10.1016/j.hemonc.2021.09.001
Abstract: OBJECTIVE/BACKGROUND Despite the success of chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive non-Hodgkin lymphoma (aNHL), some patients still fail treatment, and their prognosis is dismal. METHODS We performed a retrospective study of… read more here.
Keywords: axicabtagene ciloleucel; patients aggressive; axi cel; therapy ... See more keywords
Navigating the economic value of treatment sequencing in large B-cell lymphoma: Insights into optimizing value and patient outcomes of CAR T-cell and other available therapies in Brazil.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medical economics"
DOI: 10.1080/13696998.2025.2554516
Abstract: Abstract Background The advent of chimeric antigen receptor t-cell therapy (CAR T) has ushered in a new treatment paradigm in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) in which patients have the potential… read more here.
Keywords: value; treatment; axi cel; car ... See more keywords
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2171994
Abstract: ABSTRACT Background In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority… read more here.
Keywords: zuma; axi cel; analysis; relapsed refractory ... See more keywords
Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven
Sign Up to like & getrecommendations! Published in 2024 at "Acta Clinica Belgica"
DOI: 10.1080/17843286.2024.2399365
Abstract: ABSTRACT Introduction Large B-cell lymphomas (LBCL) are the most frequently aggressive B-cell non-Hodgkin lymphomas. Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has emerged as a new, powerful treatment for relapsed or refractory (R/R) disease. Two… read more here.
Keywords: cel; axi cel; car cell; tisa cel ... See more keywords
Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct019
Abstract: Introduction: Outcomes for pts with refractory aggressive NHL are poor with current therapies (Crump, ASCO 2016). Results from the interim analysis of (n=62) of ZUMA-1, the 1st multicenter trial of an anti-CD19 chimeric antigen receptor… read more here.
Keywords: lymphoma; trial; response; refractory aggressive ... See more keywords
Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-127372
Abstract: Introduction: Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel) are chimeric antigen receptor (CAR) T-cell therapies that target CD19-expressing B cells. Both therapies have been approved by the United States (US) Food and Drug Administration (FDA) for… read more here.
Keywords: car cell; age; axi cel; adverse events ... See more keywords
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-208307
Abstract: Introduction: Chimeric Antigen Receptor T-cell therapy (CAR-T) and T-cell engager antibody (TCE) revolutionized relapsed refractory multiple myeloma (RRMM) and non-hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL) treatment. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)… read more here.
Keywords: cilta cel; ide cel; cel; axi cel ... See more keywords
Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-209093
Abstract: Background Axicabtagene ciloleucel (axi-cel) is an autologous CD19-targeting CAR T-cell product that has demonstrated curative potential for r/r LBCL (Neelapu et al 2023). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are… read more here.
Keywords: 2020 2021; 2022 2023; 2017 2019; axi cel ... See more keywords
Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed/refractory large B-cell lymphoma in real-life: A lysa study from the descar-T registry
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-127
Abstract: Background Axicabtagene ciloleucel (axi-cel) and Lisocabtagene maraleucel (liso-cel), two anti-CD19 CAR T-cells, have been approved as 2nd line (2L) treatment in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) for patients progressing within 12 months of first-line… read more here.
Keywords: cel; axi cel; liso cel; cel liso ... See more keywords
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-1796
Abstract: Backgroud: Relapsed or refractory (R/R) indolent non-Hodgkin lymphomas (iNHLs) are incurable diseases. Based on the ZUMA-5 study, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, has been approved by the FDA… read more here.
Keywords: relapsed refractory; axi cel; chinese population;